Development of a Quantum Dot-based Assay System for Detection of Specific HIV-1 LTR Sequence Variants
Retrovirology volume 2, Article number: P9 (2005)
Analysis of human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) sequence variation within the CCAAT/enhancer binding protein (C/EBP) and stimulating protein (Sp) transcription factor binding sites has identified variants that correlate with HIV-associated dementia (HIVD). CdSe/ZnS nanocrytsals have facilitated the investigation of nano- and peco-scale biological components. Quantum dot-conjugated oligonucleotides homologous to specific variants of Sp site III and C/EBP site I, were utilized to quantitate the relative abundance of specific LTR variants. Quantum dot-conjugated oligonucleotides containing the Sp site III 5T binding site variant (C-to-T change at position 5) or the C/EBP site I 3T site variant, were reacted with plasmid DNA containing increasing concentrations of plasmid with the homologous LTR sequence variant. The results suggest that quantum dot-conjugated oligonucleotides specific for sequence variants within the LTR can be used as reporter molecules for identification and quantitation of HIV-1 genetic variation.
About this article
Cite this article
Asante, A., Nonnemacher, M., Alexaki, A. et al. Development of a Quantum Dot-based Assay System for Detection of Specific HIV-1 LTR Sequence Variants. Retrovirology 2 (Suppl 1), P9 (2005). https://doi.org/10.1186/1742-4690-2-S1-P9